Imunon, Inc. (IMNN)
NASDAQ: IMNN · IEX Real-Time Price · USD
1.240
-0.020 (-1.59%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
11.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 500.00K | - | - |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | 500.00K | - | - |
Dec 31, 2019 | 500.00K | - | - |
Dec 31, 2018 | 500.00K | - | - |
Dec 31, 2017 | 500.00K | - | - |
Dec 31, 2016 | 500.00K | - | - |
Dec 31, 2015 | 500.00K | - | - |
Dec 31, 2014 | 500.00K | - | - |
Dec 31, 2013 | 500.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 2.00M | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 2.50M | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 2.51M | - | - |
Sep 30, 2003 | 0 | - | - |
Sep 30, 2002 | 0 | - | - |
Sep 30, 2001 | 0 | - | - |
Sep 30, 2000 | 3.42K | - | - |
Sep 30, 1999 | 0 | - | - |
Sep 30, 1998 | 174.18K | 52.93K | 43.65% |
Sep 30, 1997 | 121.26K | 47.25K | 63.85% |
Sep 30, 1996 | 74.01K | -83.61K | -53.05% |
Sep 30, 1995 | 157.62K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centogene | 53.93M |
Guardion Health Sciences | 12.06M |
Aspira Women's Health | 8.99M |
RedHill Biopharma | 6.53M |
Addex Therapeutics | 1.57M |
Avalo Therapeutics | 1.45M |
Innovative Eyewear | 1.39M |
Nexalin Technology | 158.86K |
IMNN News
- 8 days ago - IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer - GlobeNewsWire
- 27 days ago - First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial - GlobeNewsWire
- 6 weeks ago - Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 7 weeks ago - IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study - GlobeNewsWire
- 7 weeks ago - IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO - GlobeNewsWire
- 2 months ago - IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 - GlobeNewsWire
- 2 months ago - IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 - GlobeNewsWire